Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI

Inclusion Criteria:

1. Three-class (Nucleoside reverse transcriptase inhibitors (NRTI), Nonnucleoside reverse transcriptase inhibitors (NNRTI), and Protease inhibitor (PI)) treatment-experienced patients (a minimum of 3-months duration for each class) with resistance to more than one protease inhibitor on the screening virtual phenotype resistance testing.
2. Patients optimized background regimen must contain at least two active antiretrovirals including Efuvirtide, Maraviroc and integrase inhibitors.
3. Patient has been on their current (failing) protease inhibitor-containing regimen for at least 8 weeks prior to randomization.
4. An HIV-1 viral load of at least 1,000 copies/mL at screening.
5. A CD4+ cell count of at least 50 cells/mm3 at screening.

9. Acceptable screening laboratory values that indicate adequate baseline organ function.

Exclusion Criteria:

1. Previous use of Tipranavir (TPV) or Darunavir (DRV).
2. Full genotypic resistance (reported as minimal response) to Tipranavir (TPV) or Darunavir (DRV) on screening virtual phenotype:

3. Female patient of child-bearing potential who:

   has a positive serum pregnancy test at screening or during the study, is breast feeding, is planning to become pregnant, is not willing to use barrier methods of contraception or requires ethinyl estradiol administration. Barrier methods of contraception include diaphragm with spermicidal substance, condom for females, cervical caps and condoms.

4. History of Progressive Multifocal Leukoencephalopathy (PML), Visceral Kaposi's Sarcoma (KS), and/or any malignancy.
5. Any AIDS defining illness that is unresolved, symptomatic or not stable on treatment for at least 12 weeks at screening visit.
6. Use of immunomodulatory drugs (such as interferon, cyclosporin, hydroxyurea and interleukin 2) within 30 days prior to randomization.
7. Current use of systemic cytotoxic chemotherapy.
8. All contraindications listed in the product monographs of Aptivus, Prezista and Norvir.